Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Carfilzomib

In Relapsed, or Relapsed and Refractory, Multiple Myeloma

Abstract

Intravenous carfilzomib is a peptide epoxyketone, next-generation proteasome inhibitor, which has been granted accelerated approval in the US for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent (thalidomide or lenalidomide), and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Carfilzomib displays high selectivity for and irreversibly inhibits the chymotrypsin-like catalytic activity of the 20S proteasome core particle, which results in cell growth arrest and apoptosis.

In the pivotal, phase II, noncomparative trial in heavily pre-treated patients (n = 266) with relapsed and refractory multiple myeloma, intravenous carfilzomib administered in 28-day cycles for up to 12 cycles produced an overall response rate of 23.7% in the response-evaluable population. The median duration of response was 7.8 months, the median progression-free survival was 3.7 months and the median overall survival was 15.6 months.

Carfilzomib had an acceptable tolerability profile in patients with relapsed, or relapsed and refractory, multiple myeloma. There was a low incidence of grade 3 or higher peripheral neuropathy.

This is a preview of subscription content, log in to check access.

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Fig. 1
Table I
Fig. 2

References

  1. 1.

    The Merck Manual: multiple myeloma [online]. Available from URL: http://www.merckmanuals.com/professional/hematology_and_oncology/plasma_cell_disorders/multiple_myeloma.html [Accessed 2012 Sep 11]

  2. 2.

    American Cancer Society. Multiple myeloma [online]. Available from URL: http://www.cancer.org [Accessed 2012 Sep 11]

  3. 3.

    Lonial S. Relapsed multiple myeloma. Hematology Am Soc Hematol Educ Program 2010; 2010: 303–9

  4. 4.

    Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008 Mar 1; 111 (5): 2516–20

  5. 5.

    Baumeister W, Walz J, Zühl F, et al. The proteasome: paradigm of a self-compartmentalizing protease. Cell 1998 Feb 6; 92 (3): 367–80

  6. 6.

    Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007 Jul 1; 67 (13): 6383–91

  7. 7.

    Fuchs O, Provaznikova D, Marinov I, et al. Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells. Cardiovasc Hematol Disord Drug Targets 2009 Mar; 9 (1): 62–77

  8. 8.

    Arastu-Kapur S, Anderl JL, Kraus M, et al. Non-proteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 2011 May 1; 17 (9): 2734–43

  9. 9.

    Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007 Nov 1; 110 (9): 3281–90

  10. 10.

    Cavaletti G, Jakubowiak AJ. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma 2010 Jul; 51 (7): 1178–87

  11. 11.

    US FDA. Kyprolis™ (carfilzomib) for injection: US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf [Accessed 2012 Sep 11]

  12. 12.

    Parlati F, Lee SJ, Aujay M, et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 2009 Oct 15; 114(16): 3439–47

  13. 13.

    Alsina M, Trudel S, Furman RR, et al. A phase 1 single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res. Epub 2012 Jul 3

  14. 14.

    Onyx Pharmaceuticals Inc. NDA 202714, Onyx Pharmaceuticals Inc., proposed trade name: Kyprolis (carfilzomib for injection), briefing document [online]. Available from URL: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM308565.pdf [Accessed 2012 Sep 11]

  15. 15.

    O’Connor OA, Stewart AK, Vallone M, et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 2009 Nov 15; 15 (22): 7085–91

  16. 16.

    Yang J, Wang Z, Fang Y, et al. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos 2011 Oct; 39 (10): 1873–82

  17. 17.

    Niesvizky R, Vij R, Martin T, et al. Carfilzomib pharmacokinetics, safety, and activity in patients with relapsed or refractory multiple myeloma and renal dysfunction: final results [abstract no. 0890]. Haematologica 2011 Jun; 96 Suppl. 2: 370–1

  18. 18.

    Jagannath S, Vij R, Stewart K, et al. Final results of PX-171–003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM) [abstract no. 8504]. J Clin Oncol 2009 May 20; 27 (15 Suppl.)

  19. 19.

    Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171–003-A1) in patients with relapsed and refractory multiple myeloma. Blood. Epub 2012 Jul 25

  20. 20.

    Vij R, Siegel DS, Jagannath S, et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. Epub 2012 Jul 30

  21. 21.

    Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2 (PX-171–004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 2012 Jun 14; 119 (24): 5661–70

  22. 22.

    US FDA. New Drug Application (NDA) 202714, carfilzomib (Kyprolis): Food and Drug Administration briefing document, Oncologic Drugs Advisory Committee Meeting, June 20, 2012 [online]. Available from URL: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM308563.pdf [Accessed 2012 Sep 11]

  23. 23.

    Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006 Sep; 20 (9): 1467–73

  24. 24.

    Papadopoulos KP, Lee P, Singhal S, et al. A phase 1b/2 study of prolonged infusion carfilzomib in patients with relapsed and/or refractory (R/R) multiple myeloma: updated efficacy and tolerability from the completed 20/56 mg/m2 expansion cohort of PX-171–007 [abstract no. 2930]. 53rd Annual Meeting and Exposition of the American Society of Hematology; 2011 Dec 10–13; San Diego (CA)

  25. 25.

    Siegel D, Kaufman JL, Wang M, et al. A summary of safety and efficacy data achieved with long-term carfilzomib (CFZ) treatment in patients with relapsed and/or refractory multiple myeloma (R/R Mm) [abstract no. 0302]. 16th Congress of the European Hematology Association; 2011 Jun 9–12; London

  26. 26.

    US FDA. Transcript of the Oncologic Drugs Advisory Committee discussion of the New Drug Application, 202714, with the proposed trade name Kyprolis, carfilzomib, for injection [online]. Available from URL: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM314709.pdf [Accessed 2012 Sep 11]

  27. 27.

    Nooka A, Badros A, Patel P, et al. Hematologic safety data of single-agent carfilzomib in relapsed and/or refractory multiple myeloma: pooled data from four phase 2 studies [abstract no. 8086]. J Clin Oncol 2012 May 30; 30 (15 Suppl.)

  28. 28.

    Harvey RD, Lonial S, Patel P, et al. Carfilzomib dose and schedule need not be adjusted for baseline renal dysfunction, including patients on hemodialysis [abstract no. 0844]. Haematologica 2012 Jun 1; 97 Suppl. 1: 346

Download references

Acknowledgements and Disclosures

The manuscript was reviewed by A.Z. Badros, Bone Marrow Transplant Program, Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA; J. Richter, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.

Author information

Correspondence to Paul L. McCormack.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

McCormack, P.L. Carfilzomib. Drugs 72, 2023–2032 (2012). https://doi.org/10.2165/11209010-000000000-00000

Download citation

Keywords

  • Multiple Myeloma
  • Thalidomide
  • Bortezomib
  • Lenalidomide
  • Overall Response Rate